Suggestions for Streamlining and Optimizing Clinical End-Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions.
- DOI
- 10.1002/cpt.1252
- Published
- 2019 Feb
- Container
- Clinical pharmacology and therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cpt.1252,
title = {Suggestions for Streamlining and Optimizing Clinical End-Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions.},
author = {DiLiberti CE and Bon C and D'Angelo P and Gallicano K and Potvin D},
year = {2019},
journal = {Clinical pharmacology and therapeutics},
doi = {10.1002/cpt.1252},
url = {https://doi.org/10.1002/cpt.1252}
}RIS
TY - JOUR TI - Suggestions for Streamlining and Optimizing Clinical End-Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions. AU - DiLiberti CE AU - Bon C AU - D'Angelo P AU - Gallicano K AU - Potvin D PY - 2019 JO - Clinical pharmacology and therapeutics DO - 10.1002/cpt.1252 UR - https://doi.org/10.1002/cpt.1252 ER -
APA
CE, D., C, B., P, D., K, G., & D, P. (2019). Suggestions for Streamlining and Optimizing Clinical End-Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions.. Clinical pharmacology and therapeutics. https://doi.org/10.1002/cpt.1252
Source records
- pubmed · retrieved 2026-09-27T14:57:27.769Z